test

Mario Sznol MD

Professor of Medicine (Medical Oncology); Clinical Research Program Leader, Melanoma Program, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

melanoma; immunologic therapy; renal cell (kidney) carcinoma; Phase I trials


Board Certifications

1985
Internal Medicine, Board Certified
1987
Medical Oncology, Board Certified

Patient Care Locations

mario_sznolfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and StomachA Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Melanoma, skinA Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination with GSK2141795
Lung and Melanoma, skinA Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases

Edit Profile